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has been implicated in AC-100 mechanism of action. As ondon-
toblasts and osteoblasts are from the same mesenchymal stem
cell lineage as chondroblasts, an osteochondral defect model
was chosen for a pilot study to investigate the activity of AC-100
on cartilage repair. The goat is well accepted for use in cartilage
repair studies due to the comparable stiﬂe joint size and cartilage
thickness to humans.
Methods: Fifteen skeletally mature female Spanish goats were
used to evaluate the healing response of an osteochondral
femoral condylar defect ﬁlled with a collagen sponge+AC-100 or
+saline. In each goat, a single full thickness (approximately 6
mm in diameter, 6 mm deep) cylindrical defect was created in
the anterior medial femoral condyle of the right hind leg stiﬂe
joint. A cylindrical plug cut from a collagen sponge (CollaPlug;
6mm diameter, 6mm long) was implanted into the lesion site.
The collagen sponge was saturated with the test article (saline;
AC100 2.5, 25mg/application). Post-operative treatments in-
cluded intra-articular injections (0.5mL) of the appropriate test
article into the operated knee joint at 1, 2 and 3 weeks post
surgery. On day 84 (12 weeks) after surgery, two animals from
each group, and on day 168 (24 weeks), three animals from each
group were humanely euthanized. The joints were grossly eval-
uated for speciﬁc changes relative to the medial femoral condyle
and the contacting surfaces. The operated femoral condyle was
analyzed by histology.
Results: There was good correlation between the gross evalua-
tion and the quantitative histological evaluation. The normalized
gross evaluation of the repair tissues showed AC-100 high dose
group to have better healing outcomes (score 2.9, p=0.056 vs.
saline group) than the saline control group (score 0) and the
low dose AC-100 group (score 0.7). At 24 weeks, the high dose
AC-100 group exhibited a better gross outcome (score 6.3), than
the saline control (score 4.0) and low dose AC-100 (score 5.5)
groups. At 12 weeks, the histological evaluation score (max. 28)
of the MFC lesions in the high dose AC-100 group had slightly
better healing outcomes (score 13.5) than the saline control
(score 9.0) and low dose AC-100 (score 10.0) groups, agreeing
with the gross observation scoring. At 24 weeks, the MFC lesions
in the high dose AC-100 group exhibited better outcomes (score
20.3) than the saline control (score 17.5) and low dose AC-100
(score 15.7) groups. There was no evidence of an inﬂammatory
response in any sections examined.
Conclusions: This pilot study showed a clear trend for AC-100
to promote repair of an osteochondral defect. A larger more
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Purpose: Nuclear Factor-κB is a key transcription factor that,
upon activation by pro-inﬂammatory signals like IL-1, directs the
expression of inﬂammatory and catabolic mediators that play an
important role in driving cartilage degradation in OA. Targeting
the signalling pathways that lead to NF-κB activation is a promis-
ing pharmacological approach for the treatment of OA. Essential
oils are complex mixtures of hydrophobic low molecular weight
plant secondary metabolites, composed of a huge diversity of ter-
penoids and/or phenylpropanoids that are promising samples to
screen for biological activities or modulation of molecular targets.
This work aimed at screening and identifying natural inhibitors
of NF-κB activation and subsequent gene expression with po-
tential therapeutic value in the reduction of the inﬂammatory and
catabolic responses of OA.
Methods: Essential oils isolated from plants of the Iberian ﬂora,
as Mentha piperita, Origanum virens, Lavandula luiseri or Ju-
niperus oxycedrus, were screened. The oils showing inhibitory
activity were fractionated by liquid chromatography on a silica
gel column, eluting with n−pentane and diethyl oxide. Each
fraction was then concentrated, analysed by gas chromatogra-
phy and gas chromatography-mass spectroscopy for composition
elucidation and prepared for further screening assays. Normal
human chondrocytes were isolated from the femoral condyles
of cadaveric tissue donors without macroscopic signs of arthritis
and used to evaluate the ability of the essential oils and their
fractions to inhibit IL-1-induced NO production. The human chon-
drocytic cell line, C-28/I2, was used to evaluate NF-κB activation.
Both cell culture types were treated for 30 min with each essen-
tial oil or fraction, in two different dilutions, followed by treatment
with IL-1β (30 ng/ml) for 30 min or 18 h to evaluate, respectively,
NF-κB activation, by detection of the cytoplasmic levels of IκB-α
by western blot, or NO production by the Griess reaction. The
MTT reduction assay was used to rule out cytotoxic effects.
Results: Of the essential oils tested, three reduced IL-1-induced
NO production. The greatest inhibition (79,9 ± 7.9% relatively to
IL-1) was achieved with the lowest dilution (1:5000) of the oil from
the leaves of J. oxycedrus spp. oxycedrus, a common evergreen
shrubthat grows wild throughout the Mediterranean regions. This
essential oil is predominantly composed of monoterpene hydro-
cabons, being α-pinene [2,6,6-trimethyl-bicyclo(3.1.1)hept-3-ene]
the major constituent. The fraction containing α-pinene (over 80%
of relative concentration) reduced signiﬁcantly both IL-1-induced
IκB-α degradation and NO production.
Conclusions: α-pinene is the major component of the essential
oil obtained from the leaves of J. oxycedrus spp. oxycedrus and,
as so, probably accounts for most of its ability to inhibit IL-1-
induced NO production. Moreover, the ability of the α-pinene-
containing fraction to prevent IL-1-induced NF-κB activation and
the subsequent expression of its target genes, namely iNOS,
suggests that α-pinene is promising as an anti-osteoarthritic
drug. Other fractions of this essential oil, particularly those with
oxygen-containing terpenoids, revealed activity, preventing both
IL-1-induced NO production and NF-κB activation, but further
studies are required to identify the active compound(s).
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Purpose: Interleukin-1 receptor antagonist (IL1Ra) attenuates
interleukin-1 (IL1) activity and may diminish osteoarthritis sever-
ity. Intra-articular IL1Ra injection is safe in humans, but the short
joint half-life of small proteins mandates high doses. Conjuga-
tion of a protein drug to elastin-like polypeptides (ELPs) adds a
temperature-sensitive, hydrophobic domain that promotes forma-
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tion of sub-micron sized particles at body temperature that slowly
resolubilize. This process is associated with a 25-fold increase in
protein half-life in the joint space following intra-articular admin-
istration in a rat model. In this study, a fusion protein of IL1Ra
and ELP was synthesized and demonstrates retention of in vitro
bioactivity for the IL1Ra domain.
Methods: Protein Synthesis. A human IL1Ra gene was fused
to a gene encoding an elastin sequence-containing peptide and
transformed into E. coli for protein expression. Thermal Sensitiv-
ity. Thermal sensitivity of ELP-IL1Ra was evaluated by measuring
solution turbidity and particle sizes below and above the tem-
perature transition by dynamic light scattering. In vitro release
from a thermally transitioned aggregate was quantiﬁed by ab-
sorbance spectrophotometry and compared to non-fusion ELP.
Proteolytic Degradation. In vitro ELP-IL1Ra degradation by col-
lagenase I or II was evaluated by SDS-PAGE after incubation
for 36 hours at 37°C. Fusion Domain Function. An ELISA was
used to quantify the immunoreactivity of ELP-IL1Ra, collage-
nase degradation products, and commercially available rhIL1Ra.
In vitro bioactivity of the fusion protein, collagenase degradation
products, and commercially available IL1Ra was quantiﬁed by
antagonism of IL1 stimulated (2.9 pM) proliferation of RPMI 1788
lymphocytes.
Results: Protein Expression. Fusion of the human IL1Ra to
the desired ELP yielded a 31 kDa chimeric protein. Thermal
Sensitivity. The fusion protein transitioned from monomers of
5 nm radius below 32°C, to supramolecular particles of 129
nm radius at 37°C (Figure 1). Disaggregation at 37°C occurred
with a time constant of 19 h, faster than ELP alone (27 h),
reﬂecting incorporation of the hydrophilic IL1Ra domain. Prote-
olytic Degradation. SDS-PAGE of the collagenase co-incubation
showed disappearance of ELP-IL1Ra and appearance of a 17
kDa fragment (Figure 2). Fusion Domain Function. ELP-IL1Ra
had one-eighth of the immunoreactivity of an equimolar solution
Figure 1. Dynamic light scattering for ELP-IL1Ra at 25 µM shows a transition
from monomers to larger, micron sized aggregates at sub-physiological temper-
atures
Figure 2. SDS-PAGE of ELP-IL1Ra incubation with collagenase II after 36 hours
at 37°C. The 31 kDa protein disappears yielding a 17 KDa fragment.
Figure 3. In vitro bioactivity of ELP-IL1Ra against IL1-induced lymphocite prolif-
eration. The collagenase digest fragment has signiﬁcantly more bioactivity than
the parent fusion protein, approximating that of the commercial protein.
of commercial rhIL1Ra, in contrast to the nearly equivalent im-
munoreactivity of the degradation fragment. ELP-IL1Ra was less
effective in inhibiting lymphocyte proliferation (EC50 310 ± 120
nM) than commercial rhIL1Ra (EC50 1.4 ± 0.3 nM). Bioactivity of
the degradation fragment (EC50 5.0 ± 2.3 nM) was not different
from the commercial antagonist (Figure 3).
Conclusions: Fusion of IL1Ra to ELP creates a thermally-
sensitive protein that can form an in vitro drug depot to sustain
anti-cytokine therapeutic release while preserving partial bioac-
tivity. Administration of ELP-IL1Ra should permit smaller doses
and longer dosing intervals compared to IL1Ra alone. Studies
are needed to determine actual amounts and intervals required
to achieve anti-IL1 effects in an in vivo model of IL1-induced
osteoarthritis.
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Purpose: Several clinical studies demonstrated that Glu-
cosamine Sulfate (GS) is effective in controlling osteoarthri-
tis (OA) symptoms. Moreover, GS seems to have structure-
modifying effects, based on clinical trial data showing that it can
delay radiographic joint space narrowing in knee OA patients.
However, the effects of GS at the tissue level on osteoarthritic ar-
ticular cartilage and other joint structures have not been studied
to date. The STR/ort mice develop a naturally occurring OA of
the tibiofemoral joint, and are therefore believed to be a relevant
model for human knee OA. The purpose of this study was to
investigate the effect of GS on the progression of OA in this
relevant STR/Ort mouse strain model.
Methods: STR/ort male mice were recruited at 6 months of
age (n=20-22/group). One group of animals was sacriﬁced at
this age to serve as a “basal” control. GS was administered
subcutaneously once daily at the doses of 200 and 400 mg/kg:
these doses correspond to 950 and 1900 mg daily in humans,
respectively, after allometric transformation, i.e. they are in line
with the standard oral human dose of 1500 mg once-a-day. After
3 months of daily treatment the animals were euthanized and
the knee joints collected, processed for histology and scored in a
blind fashion according to both Mankin’s (grade) and the OARSI
(grade x stage) method. Furthermore, a histomorphometric anal-
ysis was performed on the medial tibial plateau, measuring the
parameters of cartilage volume, cartilage thickness, rough (dam-
